1
|
Ahmad R, Baer E, Pile K, Collins-Fekete C, Gulliford S, Wickers S, Hawkins M. PO-1731 Investigating proton therapy as a treatment option for pregnant breast cancer patients. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03695-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
2
|
Nikou P, Nisbet A, Thompson A, Gulliford S, McClelland J. PO-1492 Characterising anatomical changes of head and neck cancer patients during radiotherapy treatment. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03456-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Bainbridge H, Dunlop A, McQuaid D, Gulliford S, Gunapala R, Ahmed M, Locke I, Nill S, Oelfke U, McDonald F. A Comparison of Isotoxic Dose-escalated Radiotherapy in Lung Cancer with Moderate Deep Inspiration Breath Hold, Mid-ventilation and Internal Target Volume Techniques. Clin Oncol (R Coll Radiol) 2022; 34:151-159. [PMID: 34503896 DOI: 10.1016/j.clon.2021.08.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 07/31/2021] [Accepted: 08/23/2021] [Indexed: 12/25/2022]
Abstract
AIMS With interest in normal tissue sparing and dose-escalated radiotherapy in the treatment of inoperable locally advanced non-small cell lung cancer, this study investigated the impact of motion-managed moderate deep inspiration breath hold (mDIBH) on normal tissue sparing and dose-escalation potential and compared this to planning with a four-dimensional motion-encompassing internal target volume or motion-compensating mid-ventilation approach. MATERIALS AND METHODS Twenty-one patients underwent four-dimensional and mDIBH planning computed tomography scans. Internal and mid-ventilation target volumes were generated on the four-dimensional scan, with mDIBH target volumes generated on the mDIBH scan. Isotoxic target dose-escalation guidelines were used to generate six plans per patient: three with a target dose cap and three without. Target dose-escalation potential, normal tissue complication probability and differences in pre-specified dose-volume metrics were evaluated for the three motion-management techniques. RESULTS The mean total lung volume was significantly greater with mDIBH compared with four-dimensional scans. Lung dose (mean and V21 Gy) and mean heart dose were significantly reduced with mDIBH in comparison with four-dimensional-based approaches, and this translated to a significant reduction in heart and lung normal tissue complication probability with mDIBH. In 20/21 patients, the trial target prescription dose cap of 79.2 Gy was achievable with all motion-management techniques. CONCLUSION mDIBH aids lung and heart dose sparing in isotoxic dose-escalated radiotherapy compared with four-dimensional planning techniques. Given concerns about lung and cardiac toxicity, particularly in an era of consolidation immunotherapy, reduced normal tissue doses may be advantageous for treatment tolerance and outcome.
Collapse
Affiliation(s)
- H Bainbridge
- Department of Radiotherapy at The Royal Marsden NHS Foundation Trust, Sutton, UK; The Institute of Cancer Research, London, UK
| | - A Dunlop
- Joint Department of Physics at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK
| | - D McQuaid
- Joint Department of Physics at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK
| | - S Gulliford
- Joint Department of Physics at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK
| | - R Gunapala
- Department of Statistics at The Royal Marsden NHS Foundation Trust, Sutton, UK
| | - M Ahmed
- Department of Radiotherapy at The Royal Marsden NHS Foundation Trust, Sutton, UK; The Institute of Cancer Research, London, UK
| | - I Locke
- Department of Radiotherapy at The Royal Marsden NHS Foundation Trust, Sutton, UK
| | - S Nill
- Joint Department of Physics at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK
| | - U Oelfke
- Joint Department of Physics at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK
| | - F McDonald
- Department of Radiotherapy at The Royal Marsden NHS Foundation Trust, Sutton, UK; The Institute of Cancer Research, London, UK.
| |
Collapse
|
4
|
Settatree S, Dunlop A, Mohajer J, Brand D, Mooney L, Ross G, Gulliford S, Harris E, Kirby A. What Can Proton Beam Therapy Achieve for Patients with Pectus Excavatum Requiring Left Breast, Axilla and Internal Mammary Nodal Radiotherapy? Clin Oncol (R Coll Radiol) 2021; 33:e570-e577. [PMID: 34226114 DOI: 10.1016/j.clon.2021.06.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 05/12/2021] [Accepted: 06/18/2021] [Indexed: 12/25/2022]
Abstract
AIMS Exposure of the heart to radiation increases the risk of ischaemic heart disease, proportionate to the mean heart dose (MHD). Radiotherapy techniques including proton beam therapy (PBT) can reduce MHD. The aims of this study were to quantify the MHD reduction achievable by PBT compared with volumetric modulated arc therapy in breath hold (VMAT-BH) in patients with pectus excavatum (PEx), to identify an anatomical metric from a computed tomography scan that might indicate which patients will achieve the greatest MHD reductions from PBT. MATERIALS AND METHODS Sixteen patients with PEx (Haller Index ≥2.7) were identified from radiotherapy planning computed tomography images. Left breast/chest wall, axilla (I-IV) and internal mammary node (IMN) volumes were delineated. VMAT and PBT plans were prepared, all satisfying target coverage constraints. Signed-rank comparisons of techniques were undertaken for the mean dose to the heart, ipsilateral lung and contralateral breast. Spearman's rho correlations were calculated for anatomical metrics against MHD reduction achieved by PBT. RESULTS The mean MHD for VMAT-BH plans was 4.1 Gy compared with 0.7 Gy for PBT plans. PBT reduced MHD by an average of 3.4 Gy (range 2.8-4.4 Gy) compared with VMAT-BH (P < 0.001). PBT significantly reduced the mean dose to the ipsilateral lung (4.7 Gy, P < 0.001) and contralateral breast (2.7 Gy, P < 0.001). The distance (mm) at the most inferomedial extent of IMN volume (IMN to heart distance) negatively correlated with MHD reduction achieved by PBT (Spearman's rho -0.88 (95% confidence interval -0.96 to -0.67, P < 0.001)). CONCLUSION For patients with PEx requiring left-sided breast and IMN radiotherapy, a clinically significant MHD reduction is achievable using PBT, compared with the optimal photon technique (VMAT-BH). This is a patient group in whom PBT could have the greatest benefit.
Collapse
Affiliation(s)
- S Settatree
- The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK.
| | - A Dunlop
- The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK
| | - J Mohajer
- The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK
| | - D Brand
- The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK
| | - L Mooney
- The Royal Marsden Hospital, London, UK
| | - G Ross
- The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK
| | - S Gulliford
- Department of Radiotherapy Physics, University College London Hospital, UK; Department of Medical Physics and Bioengineering, University College London, UK
| | - E Harris
- The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK
| | - A Kirby
- The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK
| |
Collapse
|
5
|
Jackson C, Allington L, Chang Y, McClelland J, Gulliford S. PO-1976 Has the Covid-19 Pandemic increased willingness to engage with remote collection of outcome data? Radiother Oncol 2021. [PMCID: PMC8629146 DOI: 10.1016/s0167-8140(21)08427-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Settatree S, Bertolet A, Carabe A, Lines D, Harrold N, Harris E, Kirby A, Gulliford S. PO-1910 Proton therapy in breast cancer: how do different beam arrangements affect linear energy transfer? Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08361-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
7
|
Wong SL, Alshaikhi J, Grimes H, Amos RA, Poynter A, Rompokos V, Gulliford S, Royle G, Liao Z, Sharma RA, Mendes R. Retrospective Planning Study of Patients with Superior Sulcus Tumours Comparing Pencil Beam Scanning Protons to Volumetric-Modulated Arc Therapy. Clin Oncol (R Coll Radiol) 2021; 33:e118-e131. [PMID: 32798157 PMCID: PMC7883303 DOI: 10.1016/j.clon.2020.07.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Revised: 05/30/2020] [Accepted: 07/22/2020] [Indexed: 12/25/2022]
Abstract
AIMS Twenty per cent of patients with non-small cell lung cancer present with stage III locally advanced disease. Precision radiotherapy with pencil beam scanning (PBS) protons may improve outcomes. However, stage III is a heterogeneous group and accounting for complex tumour motion is challenging. As yet, it remains unclear as to whom will benefit. In our retrospective planning study, we explored if patients with superior sulcus tumours (SSTs) are a select cohort who might benefit from this treatment. MATERIALS AND METHODS Patients with SSTs treated with radical radiotherapy using four-dimensional planning computed tomography between 2010 and 2015 were identified. Tumour motion was assessed and excluded if greater than 5 mm. Photon volumetric-modulated arc therapy (VMAT) and PBS proton single-field optimisation plans, with and without inhomogeneity corrections, were generated retrospectively. Robustness analysis was assessed for VMAT and PBS plans involving: (i) 5 mm geometric uncertainty, with an additional 3.5% range uncertainty for proton plans; (ii) verification plans at maximal inhalation and exhalation. Comparative dosimetric and robustness analyses were carried out. RESULTS Ten patients were suitable. The mean clinical target volume D95 was 98.1% ± 0.4 (97.5-98.8) and 98.4% ± 0.2 (98.1-98.9) for PBS and VMAT plans, respectively. All normal tissue tolerances were achieved. The same four PBS and VMAT plans failed robustness assessment. Inhomogeneity corrections minimally impacted proton plan robustness and made it worse in one case. The most important factor affecting target coverage and robustness was the clinical target volume entering the spinal canal. Proton plans significantly reduced the mean lung dose (by 21.9%), lung V5, V10, V20 (by 47.9%, 36.4%, 12.1%, respectively), mean heart dose (by 21.4%) and thoracic vertebra dose (by 29.2%) (P < 0.05). CONCLUSIONS In this planning study, robust PBS plans were achievable in carefully selected patients. Considerable dose reductions to the lung, heart and thoracic vertebra were possible without compromising target coverage. Sparing these lymphopenia-related organs may be particularly important in this era of immunotherapy.
Collapse
Affiliation(s)
- S-L Wong
- University College London Cancer Institute, London, UK; Department of Clinical Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
| | - J Alshaikhi
- Department of Medical Physics and Biomedical Engineering, University College London, London, UK; Department of Radiotherapy Physics, University College London Hospitals NHS Foundation Trust, London, UK; Saudi Particle Therapy Centre, Riyadh, Saudi Arabia
| | - H Grimes
- Department of Radiotherapy Physics, University College London Hospitals NHS Foundation Trust, London, UK
| | - R A Amos
- Department of Clinical Oncology, University College London Hospitals NHS Foundation Trust, London, UK; Department of Radiotherapy Physics, University College London Hospitals NHS Foundation Trust, London, UK; Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - A Poynter
- Department of Radiotherapy Physics, University College London Hospitals NHS Foundation Trust, London, UK
| | - V Rompokos
- Department of Radiotherapy Physics, University College London Hospitals NHS Foundation Trust, London, UK
| | - S Gulliford
- Department of Medical Physics and Biomedical Engineering, University College London, London, UK; Department of Radiotherapy Physics, University College London Hospitals NHS Foundation Trust, London, UK
| | - G Royle
- Department of Medical Physics and Biomedical Engineering, University College London, London, UK
| | - Z Liao
- Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - R A Sharma
- University College London Cancer Institute, London, UK; Department of Clinical Oncology, University College London Hospitals NHS Foundation Trust, London, UK; NIHR University College London Hospitals Biomedical Research Centre, London, UK
| | - R Mendes
- Department of Clinical Oncology, University College London Hospitals NHS Foundation Trust, London, UK
| |
Collapse
|
8
|
Lowe M, Gosling A, Nicholas O, Underwood T, Miles E, Chang YC, Amos RA, Burnet NG, Clark CH, Patel I, Tsang Y, Sisson N, Gulliford S. Comparing Proton to Photon Radiotherapy Plans: UK Consensus Guidance for Reporting Under Uncertainty for Clinical Trials. Clin Oncol (R Coll Radiol) 2020; 32:459-466. [PMID: 32307206 DOI: 10.1016/j.clon.2020.03.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 03/11/2020] [Accepted: 03/30/2020] [Indexed: 12/11/2022]
Abstract
In the UK, the recent introduction of high-energy proton beam therapy into national clinical practice provides an opportunity for new clinical trials, particularly those comparing proton and photon treatments. However, comparing these different modalities can present many challenges. Although protons may confer an advantage in terms of reduced normal tissue dose, they can also be more sensitive to uncertainty. Uncertainty analysis is fundamental in ensuring that proton plans are both safe and effective in the event of unavoidable discrepancies, such as variations in patient setup and proton beam range. Methods of evaluating and mitigating the effect of these uncertainties can differ from those approaches established for photon therapy treatments, such as the use of expansion margins to assure safety. These differences should be considered when comparing protons and photons. An overview of the effect of uncertainties on proton plans is presented together with an introduction to some of the concepts and terms that should become familiar to those involved in proton therapy trials. This report aims to provide guidance for those engaged in UK clinical trials comparing protons and photons. This guidance is intended to take a pragmatic approach considering the tools that are available to practising centres and represents a consensus across multidisciplinary groups involved in proton therapy in the UK.
Collapse
Affiliation(s)
- M Lowe
- Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, The University of Manchester, Manchester, UK.
| | - A Gosling
- Department of Radiotherapy Physics, University College London Hospitals NHS Foundation Trust, London, UK
| | - O Nicholas
- South West Wales Cancer Centre, Swansea Bay NHS Trust, Swansea, UK; Swansea University Medical School, Swansea University, Swansea, UK; National Radiotherapy Trials Quality Assurance Group, Velindre Cancer Centre, Cardiff, UK
| | - T Underwood
- Division of Cancer Sciences, School of Medical Sciences, The University of Manchester, Manchester, UK
| | - E Miles
- National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, Middlesex, UK
| | - Y-C Chang
- Department of Radiotherapy, University College London Hospitals NHS Foundation Trust, London, UK
| | - R A Amos
- Proton and Advanced Radiotherapy Group, Department of Medical Physics and Biomedical Engineering, University College London, London, UK
| | - N G Burnet
- Division of Cancer Sciences, School of Medical Sciences, The University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK
| | - C H Clark
- National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, Middlesex, UK
| | - I Patel
- Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, The University of Manchester, Manchester, UK
| | - Y Tsang
- National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, Middlesex, UK
| | - N Sisson
- National Radiotherapy Trials Quality Assurance Group, The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, UK
| | - S Gulliford
- Department of Radiotherapy Physics, University College London Hospitals NHS Foundation Trust, London, UK; Department of Medical Physics and Biomedical Engineering, University College London, London, UK
| |
Collapse
|
9
|
Settatree S, Brand D, Ranger A, Dunlop A, Harris E, Gulliford S, Kirby A. Estimating Contralateral Breast Cancer Risk from Photons versus Protons in Patients Undergoing Internal Mammary Nodal Breast Cancer Radiotherapy. Clin Oncol (R Coll Radiol) 2020; 32:342. [PMID: 31948769 DOI: 10.1016/j.clon.2019.12.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Accepted: 12/13/2019] [Indexed: 11/22/2022]
Affiliation(s)
- S Settatree
- The Royal Marsden Hospital, London, UK; The Institute Cancer Research, London, UK
| | - D Brand
- The Royal Marsden Hospital, London, UK; The Institute Cancer Research, London, UK
| | - A Ranger
- The Royal Marsden Hospital, London, UK; The Institute Cancer Research, London, UK
| | - A Dunlop
- The Royal Marsden Hospital, London, UK; The Institute Cancer Research, London, UK
| | - E Harris
- The Institute Cancer Research, London, UK
| | - S Gulliford
- University College London Hospital, London, UK
| | - A Kirby
- The Royal Marsden Hospital, London, UK; The Institute Cancer Research, London, UK
| |
Collapse
|
10
|
Naismith O, Mayles H, Bidmead M, Clark CH, Gulliford S, Hassan S, Khoo V, Roberts K, South C, Hall E, Dearnaley D. Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer. Clin Oncol (R Coll Radiol) 2019; 31:611-620. [PMID: 31201110 DOI: 10.1016/j.clon.2019.05.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Revised: 04/01/2019] [Accepted: 04/12/2019] [Indexed: 10/26/2022]
Abstract
AIMS The CHHiP trial investigated the use of moderate hypofractionation for the treatment of localised prostate cancer using intensity-modulated radiotherapy (IMRT). A radiotherapy quality assurance programme was developed to assess compliance with treatment protocol and to audit treatment planning and dosimetry of IMRT. This paper considers the outcome and effectiveness of the programme. MATERIALS AND METHODS Quality assurance exercises included a pre-trial process document and planning benchmark cases, prospective case reviews and a dosimetry site visit on-trial and a post-trial feedback questionnaire. RESULTS In total, 41 centres completed the quality assurance programme (37 UK, four international) between 2005 and 2010. Centres used either forward-planned (field-in-field single phase) or inverse-planned IMRT (25 versus 17). For pre-trial quality assurance exercises, 7/41 (17%) centres had minor deviations in their radiotherapy processes; 45/82 (55%) benchmark plans had minor variations and 17/82 (21%) had major variations. One hundred prospective case reviews were completed for 38 centres. Seventy-one per cent required changes to clinical outlining pre-treatment (primarily prostate apex and base, seminal vesicles and penile bulb). Errors in treatment planning were reduced relative to pre-trial quality assurance results (49% minor and 6% major variations). Dosimetry audits were conducted for 32 centres. Ion chamber dose point measurements were within ±2.5% in the planning target volume and ±8% in the rectum. 28/36 films for combined fields passed gamma criterion 3%/3 mm and 11/15 of IMRT fluence film sets passed gamma criterion 4%/4 mm using a 98% tolerance. Post-trial feedback showed that trial participation was beneficial in evolving clinical practice and that the quality assurance programme helped some centres to implement and audit prostate IMRT. CONCLUSION Overall, quality assurance results were satisfactory and the CHHiP quality assurance programme contributed to the success of the trial by auditing radiotherapy treatment planning and protocol compliance. Quality assurance supported the introduction of IMRT in UK centres, giving additional confidence and external review of IMRT where it was a newly adopted technique.
Collapse
Affiliation(s)
- O Naismith
- Royal Marsden NHS Foundation Trust, London, UK.
| | - H Mayles
- Clatterbridge Cancer Centre, Bebington, Wirral, UK
| | - M Bidmead
- Royal Marsden NHS Foundation Trust, London, UK
| | - C H Clark
- Royal Surrey County Hospital, Guildford, UK
| | - S Gulliford
- The Institute of Cancer Research, London, UK
| | - S Hassan
- The Institute of Cancer Research, London, UK
| | - V Khoo
- Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
| | - K Roberts
- Royal Marsden NHS Foundation Trust, London, UK
| | - C South
- Royal Surrey County Hospital, Guildford, UK
| | - E Hall
- The Institute of Cancer Research, London, UK
| | - D Dearnaley
- Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
| | | |
Collapse
|
11
|
Bhattacharya I, Haviland J, Perotti C, Eaton D, Gulliford S, Harris E, Coles C, Kirwan C, Bliss J, Kirby A. OC-0595 Does seroma predict patient-reported adverse effects following breast radiotherapy in IMPORT HIGH? Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31015-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
12
|
Otter S, Wedlake L, McNair H, Lawes R, Juman C, Andreyev J, Stewart A, Gulliford S. Defining Bowel and Nonsigmoid Bowel Dose Volume Constraints for Pelvic Radiation Therapy in GI Malignancies. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Reis Ferreira M, Andreyev H, Gulliford S, Mohammed K, Marchesi J, Dearnaley D. PV-0624: Longitudinal analysis of the microbiota by GI toxicity during IMRT for high-risk prostate cancer. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30934-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
14
|
Gulliford S, Griffin C, Tree A, Murray J, Oelfke U, Syndikus I, Hall E, Dearnaley D. EP-1612: Estimates of the α/β ratio for prostate using data from recent hypofractionated RT trials. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)32047-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
15
|
Humbert-Vidan L, Gulliford S, Patel V, Thomas C, Guerrero-Urbano T. EP-1603: Atlas of complication incidence to explore dosimetric contributions to osteoradionecrosis. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)32038-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Khan A, Thomas K, Truelove L, Ferreira M, Gulliford S, McNair H, Parker C, Huddart R, Dearnaley D. EP-1363: Clinical efficacy of a dose escalated and hypofractionated pelvic IMRT study in prostate cancer. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31798-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Murray J, Dean J, Mossop H, Hall E, Dearnaley D, Gulliford S. Effect of Dose to the Penile Bulb on Erectile Potency (EP) in Prostate Image-guided Radiotherapy (IGRT). Clin Oncol (R Coll Radiol) 2017. [DOI: 10.1016/j.clon.2016.11.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Dearnaley D, Syndikus I, Gulliford S, Hall E. Hypofractionation for Prostate Cancer: Time to Change. Clin Oncol (R Coll Radiol) 2017; 29:3-5. [PMID: 27777147 DOI: 10.1016/j.clon.2016.09.020] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2016] [Accepted: 09/26/2016] [Indexed: 10/20/2022]
Affiliation(s)
- D Dearnaley
- The Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK.
| | - I Syndikus
- Clatterbridge Centre for Oncology, Bebington, UK
| | - S Gulliford
- The Institute of Cancer Research, London, UK
| | - E Hall
- The Institute of Cancer Research, London, UK
| |
Collapse
|
19
|
Dearnaley D, Syndikus I, Hall E, Gulliford S. Response to: Sivanandan et al. Prostate Hypofractionated Radiotherapy Trial Results Need to be Interpreted with Caution due to Undertreatment of the Control Arm in the CHHiP Trial. Clin Oncol (R Coll Radiol) 2016; 28:798-799. [PMID: 27640308 DOI: 10.1016/j.clon.2016.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2016] [Accepted: 09/01/2016] [Indexed: 11/17/2022]
Affiliation(s)
- D Dearnaley
- The Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK
| | | | - E Hall
- The Institute of Cancer Research, London, UK
| | - S Gulliford
- The Institute of Cancer Research, London, UK
| |
Collapse
|
20
|
Murray J, Dean J, Mossop H, Griffin C, Hall E, Gulliford S, Dearnaley D. Effect of Dose and Image Guided Radiation Therapy (IGRT) on Patient-Reported Sexual Function in Prostate Radiation Therapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1207] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Reis Ferreira M, Gulliford S, Thomas K, Truelove L, McNair H, Dearnaley D. EP-1378: Should pelvic radiotherapy be tailored to early patient-reported gastrointestinal toxicity? Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32628-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
McDonald F, Waters R, Gulliford S, Hall E, James N, Huddart RA. Defining bowel dose volume constraints for bladder radiotherapy treatment planning. Clin Oncol (R Coll Radiol) 2015; 27:22-9. [PMID: 25445550 DOI: 10.1016/j.clon.2014.09.016] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2014] [Revised: 09/01/2014] [Accepted: 09/23/2014] [Indexed: 10/24/2022]
Abstract
AIMS Increases to radiotherapy dose are constrained by normal tissue effects. The relationship between bowel dose volume data and late bowel toxicity in patients with muscle-invasive bladder cancer treated with radical radiotherapy was assessed. MATERIALS AND METHODS The bowel was contoured retrospectively on radiotherapy plans of 47 patients recruited to the BC2001 trial (CRUK/01/004). The relationship between bowel volume at various dose levels and prospectively collected late bowel toxicity was explored. RESULTS Fifteen per cent and 6% of patients experienced grade 1 and grade 2 or more late bowel toxicity, respectively. The mean bowel volume was significantly less at doses ≥50 Gy in those treated with reduced high dose volume radiotherapy compared with standard radiotherapy. The probability of late bowel toxicity increased as bowel volume increased (P ≤ 0.05 for dose levels 30-50 Gy). No grade 2 or more late bowel toxicity was observed in patients with bowel volumes under the thresholds given in the model that predict for 25% probability of late bowel toxicity. CONCLUSIONS There is a dose volume effect for late bowel toxicity in radical bladder radiotherapy. We have modelled the probability of late bowel toxicity from absolute bowel volumes to guide clinicians in assessing radical bladder radiotherapy plans. Thresholds predicting for a 25% probability of late bowel toxicity are proposed as dose volume constraints.
Collapse
Affiliation(s)
- F McDonald
- Academic Radiotherapy Unit, Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
| | - R Waters
- Clinical Trials and Statistics Unit, Institute of Cancer Research, London, UK
| | - S Gulliford
- Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
| | - E Hall
- Clinical Trials and Statistics Unit, Institute of Cancer Research, London, UK
| | - N James
- Clinical Trials Unit Gibbet Hill Campus, University of Warwick, Coventry, UK
| | - R A Huddart
- Academic Radiotherapy Unit, Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.
| |
Collapse
|
23
|
Murray J, Gulliford S, Alexander E, Mcnair H, Dearnaley D. P028 The effect of ProSpare, a rectal obturator on anorectal doses in prostate radiotherapy. ACTA ACUST UNITED AC 2014. [DOI: 10.1016/s1569-9056(14)61253-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
24
|
Dean J, Welsh L, Gulliford S, Harrington K, Nutting C. SU-D-16A-02: A Novel Methodology for Accurate, Semi-Automated Delineation of Oral Mucosa for Radiation Therapy Dose-Response Studies. Med Phys 2014. [DOI: 10.1118/1.4887858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
25
|
Murray J, McQuaid D, Dunlop A, Buettner F, Nill S, Hall E, Dearnaley D, Gulliford S. SU-E-J-14: A Novel Approach to Evaluate the Dosimetric Effect of Rectal Variation During Image Guided Prostate Radiotherapy. Med Phys 2014. [DOI: 10.1118/1.4888065] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
26
|
Ebert M, Gulliford S, Foo K, Haworth A, Kennedy A, Joseph D, Denham J. PD-0547: GI dose constraints for prostate radiotherapy: Derivation by toxicity and localised anatomy. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30653-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
27
|
Gulliford S. SP-0396: Machine learning approaches to modelling dose-volume effects. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)32702-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
28
|
Schick U, Gulliford S, Zaidi S, Lal P, Franzese C, Gujral D, Newbold K, Nutting C, Harrington K, Bhide S. EP-1015: Predictors of acute dysphagia and oral mucositis in head and neck patients treated with chemoradiotherapy. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)33321-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
29
|
Buettner F, Alexander E, McNair H, Bulbrook L, Gulliford S, Partridge M, Dearnaley D. SU-E-T-255: A Novel Rectal Obturator for Prostate Radiotherapy Improves the Spatial Distribution of Dose and Reduces the Predicted Risk for Rectal Bleeding and Subjective Sphincter Control. Med Phys 2012; 39:3762. [PMID: 28517352 DOI: 10.1118/1.4735322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE To investigate the effects of an endorectal device during prostate radiotherapy on the spatial distribution of dose to the ano-rectal region and quantify implications for normal-tissue-complication probabilities. METHODS Twenty-three patients with localised prostate cancer, referred for external beam radiotherapy had 2 CT scans acquired, without and with the rectal obturator (ProSpare) in-situ. For each patient two dose distributions were generated, based on both CT scans. Dose-surface maps for the rectal surface and the anal surface were generated and mean dose as well as a spatial measure (circumference of the dose distribution) were determined for all patients, with and without ProSpare. Using previously published NTCP models, the effect of ProSpare on NTCP was investigated for rectal bleeding and subjective sphincter control. RESULTS In a previous study subjective sphincter control correlated strongest with mean dose and lateral extent at 53 Gy. The use of ProSpare resulted in a highly significant reduction of the lateral extent at 53 Gy (p=0.006), mean dose (p=0.0009) and NTCP according to the LKB model (p=0.002 for grade 2 and p=0.001 for grade >=1). In a previous study we reported that rectal bleeding correlated most strongly with the lateral extent at 55 Gy and presented the constraint that it should not exceed 42% of the circumference. Using ProSpare resulted in a significant reduction of the lateral extent at 55 Gy (p=0.001) and significantly more patients met that proposed constraint (p=0.047). ProSpare resulted in a significant reduction of NTCP for grade-2 rectal bleeding (p=0.007) and a reduction for rectal bleeding grade >=1 (p=0.053). CONCLUSIONS ProSpare resulted in a significant reduction of mean dose to the anal sphincter and a significant reduction of the lateral extent at 55 Gy. This corresponded to a significant reduction in the predicted risk of reporting subjective sphincter control and grade-2 rectal bleeding.
Collapse
Affiliation(s)
- F Buettner
- Helmholtz-Zentrum Muenchen, Munich, Germany.,Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.,Royal Marsden NHS Foundation Trust, Sutton, UK
| | - E Alexander
- Helmholtz-Zentrum Muenchen, Munich, Germany.,Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.,Royal Marsden NHS Foundation Trust, Sutton, UK
| | - H McNair
- Helmholtz-Zentrum Muenchen, Munich, Germany.,Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.,Royal Marsden NHS Foundation Trust, Sutton, UK
| | - L Bulbrook
- Helmholtz-Zentrum Muenchen, Munich, Germany.,Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.,Royal Marsden NHS Foundation Trust, Sutton, UK
| | - S Gulliford
- Helmholtz-Zentrum Muenchen, Munich, Germany.,Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.,Royal Marsden NHS Foundation Trust, Sutton, UK
| | - M Partridge
- Helmholtz-Zentrum Muenchen, Munich, Germany.,Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.,Royal Marsden NHS Foundation Trust, Sutton, UK
| | - D Dearnaley
- Helmholtz-Zentrum Muenchen, Munich, Germany.,Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.,Royal Marsden NHS Foundation Trust, Sutton, UK
| |
Collapse
|
30
|
Van der Geest A, Buettner F, Gulliford S, Partridge M, Webb S, Dearnaley D, Sydes M, Kaanders J, Smeenk R, van Lin E. 447 poster RELATIONSHIP BETWEEN DOSE DISTRIBUTION ON THE RECTAL WALL AND LATE TOXICITY AFTER PROSTATE RT WITH ENDOREC-TAL BALLOON. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70569-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
Buettner F, Gulliford S, Webb S, Sydes M, Dearnaley D, Partridge M. 448 poster CORRELATIONS BETWEEN 3D DOSE DISTRIBUTION TO THE ANAL SURFACE AND LATE RECTAL TOXICITY AFTER PROSTATE RADIOTHERAPY. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70570-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
32
|
Mian A, Gulliford S, Bhide S, Newbold K, Harrington K, Nutting C. DOSE VOLUME HISTOGRAM ATLASES OF XEROSTOMIA INCIDENCE: AN ALTERNATIVE PREDICTOR OF RECOVERY OF SALIVARY FUNCTION. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)71769-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Buettner F, Miah A, Gulliford S, Harrington K, Webb S, Partridge M, Nutting C. A NOVEL DOSE-RESPONSE MODEL FOR XEROSTOMIA ALLOWING FOR REGIONAL VARIATIONS IN RADIO-SENSITIVITY OF THE PAROTID. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)71718-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
34
|
Buettner F, Mian A, Gulliford S, Harrington K, Webb S, Partridge M, Nutting C. A NOVEL APPROACH TO MODELLING XEROSTOMIA BASED ON THE SHAPE OF THE 3D DOSE-DISTRIBUTION AND CLINICAL FACTORS. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70089-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Bhide S, Gulliford S, A'Hern R, Hall E, Newbold K, Harrington K, Nutting C. Quantitative Estimates of the Effects of Concomitant Chemotherapy on Acute Dysphagia in Patients Receiving Radical Treatment for Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.1400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
36
|
Bhide S, Gulliford S, A'Hern R, Hall E, Newbold K, Harrington K, Nutting C. Quantitative estimates of the effects of concomitant chemotherapy on acute dysphagia in patients receiving radical treatment for head and neck cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22134 Purpose: To generate quantitative parameters describing the effect of concomitant chemotherapy on incidence of grade 3 dysphagia (CTCAE v3.0, assisted feeding) using dose response curves in patients receiving radical treatment for head and neck cancer. Methods: Patients treated at a single centre in prospective phase I and II trials of concomitant chemo-IMRT (CRT) (n=85) and the phase III trial of IMRT vs. conventional radiotherapy (PARSPORT) (n=82) formed the basis of this non-randomized comparison. Patients in the PARSPORT trial received radiation alone (RT). Radiation dose for all patients was radiobiologically equivalent to at least 70Gy in 35 fractions. Concomitant chemotherapy was cisplatin (100 mg/m2) on days 1 and 29. G3 dysphagia was recorded prospectively. Dose volume histograms (DVH) were generated for the pharyngeal mucosa. The mean dose (converted to equivalent dose in 2Gy/fraction, MD2) was used as a univariate descriptor of the DVH, for the generation of the dose response curves. A logistic function of the form p=1/[1+(MD50/D)k] was fitted where, p is the probability of the incidence of toxicity, D is the mean dose, MD50 is the mean dose at which 50% of patients experience toxicity and k describes the increase in incidence with increasing dose. The dose response curves were fitted using non-linear logistic regression. Results: The mean MD2 to the pharyngeal mucosa were 56Gy and 55.8Gy respectively, in the CRT and RT groups. There was a statistically significant difference of 25% (95% CI: 10–38, p=0.002) in the incidence of G3 dysphagia between the CRT (68%) and RT (43%) groups. Fitting dose response curves to the clinical data yielded parameter values (95% CIs) of MD50=46 Gy (42–49), k=4.8 (2.3–7.2) for the CRT group and MD50= 58 Gy (55–61), k=3 (1.6-.45) for RT group. Dose response gradients for CRT and RT showed approximately 1.95% and 1.3% increase (respectively) in probability of G3 dysphagia resulting from an increase in mean dose of 1Gy between doses of 30Gy to 70Gy. Conclusions: Addition of concomitant chemotherapy increases the incidence of G3 dysphagia by 0.65% for every 1 Gy increase in radiation dose. The observed MD50 for G3 dysphagia is lower for RT alone (46 Gy vs. 58 Gy). No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Bhide
- University College Hospitals, London, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; ICR-CTSU, Sutton, United Kingdom; Royal Marsden Hospital & ICR, London, United Kingdom; Rotal Marsden Hospital, London, United Kingdom
| | - S. Gulliford
- University College Hospitals, London, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; ICR-CTSU, Sutton, United Kingdom; Royal Marsden Hospital & ICR, London, United Kingdom; Rotal Marsden Hospital, London, United Kingdom
| | - R. A'Hern
- University College Hospitals, London, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; ICR-CTSU, Sutton, United Kingdom; Royal Marsden Hospital & ICR, London, United Kingdom; Rotal Marsden Hospital, London, United Kingdom
| | - E. Hall
- University College Hospitals, London, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; ICR-CTSU, Sutton, United Kingdom; Royal Marsden Hospital & ICR, London, United Kingdom; Rotal Marsden Hospital, London, United Kingdom
| | - K. Newbold
- University College Hospitals, London, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; ICR-CTSU, Sutton, United Kingdom; Royal Marsden Hospital & ICR, London, United Kingdom; Rotal Marsden Hospital, London, United Kingdom
| | - K. Harrington
- University College Hospitals, London, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; ICR-CTSU, Sutton, United Kingdom; Royal Marsden Hospital & ICR, London, United Kingdom; Rotal Marsden Hospital, London, United Kingdom
| | - C. Nutting
- University College Hospitals, London, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; ICR-CTSU, Sutton, United Kingdom; Royal Marsden Hospital & ICR, London, United Kingdom; Rotal Marsden Hospital, London, United Kingdom
| |
Collapse
|
37
|
Gulliford S, Partridge M, Webb S, Evans P, Foo K, Morgan R, Sydes M, Dearnaley D. WE-C-AUD B-04: Normal Tissue Complication Probability: Updating the Model Parameters for Modern Radiotherapy. Med Phys 2008. [DOI: 10.1118/1.2962691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
38
|
Gulliford S. 97 Artificial Neural Networks in Radiotherapy Optimization. Radiother Oncol 2005. [DOI: 10.1016/s0167-8140(05)81074-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
39
|
James H, Gulliford S, MacKenzie C, Le Vay J, Sherwin E, Smith S, Hardy V, Poynter A. 379 Applications of IMRT for breast related progressive disease. Radiother Oncol 2005. [DOI: 10.1016/s0167-8140(05)81355-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
40
|
Gulliford S, James H, MacKenzie C, Le Vay J, Sherwin E, Smith S, Perry R, Poynter A. 224 Dosimetric implications of intentional skin dose with IMRT. Radiother Oncol 2005. [DOI: 10.1016/s0167-8140(05)81201-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
41
|
Abstract
In this paper we discuss a study comparing an algorithm implemented clinically to design intensity-modulated fields with two artificial neural networks (ANNs) trained to design the same fields. The purpose of the algorithm is to produce compensation for tangential breast radiotherapy in order to improve dose homogeneity. This was achieved by creating intensity-modulated fields to supplement standard wedged fields. Portal image data were used to create thickness maps of the medial and lateral fields, which in turn were used to design the wedged and intensity-modulated fields. The ANNs were developed to design the intensity-modulated fields from the portal image data and corresponding fluence map alone. One used localized groups of portal image pixels related to the fluence map (method 2), and the other used a one-to-one mapping between spatially corresponding pixels (method 3). A dosimetric comparison of the methods was performed by calculating the overall dose distribution. The volume of tissue outside the dose range 95-105% was used to assess dose homogeneity. The average volume outside 95-105%, averaged over 80 cases, was shown to be 2.3% for the algorithm, whilst average values of 9.9% and 13.5% were obtained for methods 2 and 3, respectively. The results of this study demonstrate the ability of an ANN to learn the general shape of compensation required and explore the use of image-based ANNs in the design of intensity-modulated fields.
Collapse
Affiliation(s)
- S Gulliford
- Joint Department of Physics, Institute of Cancer Research and Royal Marsden Hospital NHS Trust, Sutton, Surrey, UK.
| | | | | | | |
Collapse
|